Is Mirum Pharmaceuticals on a Strong Path to Profitability?

2026-01-31 15:22:00 ET

Mirum Pharmaceuticals (NASDAQ: MIRM) , a mid-cap biotech, performed well last year and is maintaining that momentum so far in 2026. The company's shares have more than doubled over the trailing 12-month period.

However, as is almost always the case with smaller drugmakers, Mirum Pharmaceuticals isn't consistently profitable. If it can make solid progress toward that goal (and elsewhere), the stock might be worth investing in today. Is Mirum close to posting consistent green on the bottom line?

Image source: Getty Images.

Continue reading